Sitagliptin Triazole Hydrochloride CAS 762240-92-6 Puritas >99.0% (HPLC)

Description:

Nomen: Sitagliptin Triazole Hydrochloride

CAS: 762240-92-6

Puritas: >99.0% (HPLC)

Aspectus: Alba ad Off-White Crystalline pulveris

Sitagliptin phosphate monohydratorum intermedium (CAS: 654671-77-9) diabete melliti tractatum.

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum 3-(Trifluoromethyl) -5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride
Synonyma Sitagliptin Triazole Hydrochloride;Sitagliptin medium A
CAS Number 762240-92-6
CATTUS Number RF-PI1193
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C6H7F3N4·HCl
M. Pondus 228.60
Liquescens punctum 236.0~ 246.0℃
Solubilitas Solutum in Methanol
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Alba ad Off-White Crystalline pulveris
Lepidium sativum ab HPLC Retention tempus specimen concordat cum reference vexillum
Lepidium sativum IR Obsequitur
Damnum in Siccatio <0.50%
Substantiae cognatae
Unam immunditiam <0.50%
Totalis immunditias <1.00%
Metalla gravis <20ppm
Puritas / Analysis Methodus >99.0% (HPLC)
Test Standard Enterprise Standard
Consuetudinem Sitagliptin Phosphate Monohydratorum medium (CAS: 654671-77-9)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

1

FAQ:

Applicatio:

3-(Trifluoromethyl) -5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinum hydrochloridum (CAS: 762240-92-6) intermedium est inter Sitagliptin Phosphatis Monohydratorum (. CAS: 654671-77-9), qui est inhibitor ore-selectivus selectivus DPP4 qui per "optimizationem ordinis β-aminoacidi-deductum DPP4 inhibitores" deprehensus est.DPP4 activitatem sustentato modo subsecuto semel cottidianam administrationem demittit, integras GIP et GLP1 gradus circulationes sequentes in studiis tam acutis quam chronicis conservat ac sanguinem glucosum minuit, sine notabili incremento in hypoglycaemia.Sitagliptin phosphatum (STG) tractare DM specie 2 adhibetur, quia imperium glycemicum auget augendo gradus incretinorum hormonum activorum, GLP-I (peptide-1) et GIP (glucoso-dependens insulinotropico peptidis).STG a FDA in 2006 probatus est.

Epistulam tuam hic scribe et mitte nobis